A Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential Hypertension

Phase 3 Completed 418 enrolled Takeda

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine the long term safety and tolerability of azilsartan medoxomil, once daily (QD), in participants with Essential Hypertension.

Timeline

Start: 2007-06
Primary completion: 2009-04
Completion: 2009-04

Publications

Kipnes MS, Handley A, Lloyd E, Barger B, Roberts A. Safety, tolerability, and efficacy of azilsartan medoxomil with or without chlorthalidone during and after 8 months of treatment for hypertension. J Clin Hypertens (Greenwich). 2015 Mar;17(3):183-92. doi: 10.1111/jch.12474. Epub 2015 Jan 24.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Azilsartan medoxomil	Other / unclassified	20 mg	Oral
Subject	Azilsartan medoxomil	Other / unclassified	40 mg	Oral
Subject	Azilsartan medoxomil	Other / unclassified	80 mg	Oral
Background	Chlorthalidone	Other / unclassified	25 mg	Oral

A Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential Hypertension

Summary

Timeline

Publications

Drugs

Indications